June 27, 2025

Botulinum Toxin and Scopolamine for Radiation-Induced Salivary Gland Toxicity in Metastatic Prostate Cancer

Injection with botulinum toxin type A plus transdermal scopolamine led to the reduction in radiation-induced salivary gland toxicity without compromising PSMA tumor uptake in patients with metastatic ...

The ASCO Post

June 27, 2025

Radiotherapy for Prostate Cancer: 2- vs 8-Week Course

The phase III HYPO-RT-PC trial has shown that a 2-week course of radiotherapy for localized prostate cancer—also known as ultra-hypofractionated radiotherapy—may be just as safe and effective as the t...

The ASCO Post

June 27, 2025

FDA Expands Indication for Lu-177 Vipivotide Tetraxetan in mCRPC

The indication for lutetium Lu-177 vipivotide tetraxetan (Pluvicto) was expanded by the FDA to include adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been t...

The ASCO Post

June 27, 2025

Localized Prostate Cancer: Long-Term Follow-up of Hypofractionated, Dose-Escalated vs Conventionally Fractionated RT

In a long-term follow-up of the phase III dose-escalated, hypofractionated prostate radiation study reported in the Journal of Clinical Oncology, Hassanzadeh et al compared hypofractionated intensity-...

The ASCO Post

June 27, 2025

FDA Approves Label Expansion for Agent Used in Patient Selection for Pre-Taxane Radioligand Therapy

The update applies to the imaging agent’s third indication, for the selection of patients who are indicated for prostate-specific membrane antigen–directed therapy.

The ASCO Post

June 27, 2025

Patient-Reported Outcomes and Symptomatic Skeletal Events With Lu-PSMA in Progressive Metastatic Castration-Resistant Prostate Cancer

In analyses from the phase III PSMAfore trial reported in The Lancet Oncology, Fizazi et al examined whether LuPSMA (vipivotide tetraxetan; Lu-PSMA) improved patient-reported outcomes and delayed the ...

The ASCO Post

June 27, 2025

Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases

In a phase II trial (PEACE V–STORM) reported in The Lancet Oncology, Ost et al evaluated whether elective nodal radiotherapy to the pelvis was associated with longer metastasis-free survival vs metast...

The ASCO Post

June 26, 2025

MRI Accurately Distinguishes Menière’s From Migraine

A new prospective study found that hydrops MRI using cochlear and vestibular imaging markers can accurately differentiate Menière’s disease from vestibular migraine, offering a non-invasive diagnostic tool for clinicians dealing with overlapping symptoms.

Conexiant

June 26, 2025

GPC3-Targeted ImmunoPET Helps Detect Earlier-Stage Hepatocellular Carcinoma

A novel immunoPET imaging agent targeting GPC3 demonstrated high sensitivity and specificity in detecting GPC3-positive hepatocellular carcinoma (HCC) tumors, according to the results of a pilot clini...

The ASCO Post